Updates are available Correction dated 2025-07-12

Article History

Received: 24 June 2024

Accepted: 18 March 2025

First Online: 12 May 2025

Change Date: 12 July 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41531-025-01068-y

Competing interests

: E. Mak, R.I. Reid, S.A. Przybelski, A.J. Fought, and T.G. Lesnick report no disclosures relevant to the manuscript. C.G. Schwarz receives research support from the NIH. J. Graff-Radford serves on the editorial board for Neurology and receives research support from NIH. M.L. Senjem owns or has owned stock in medical-related companies, unrelated to the current work, within the past 36 months: Align Technology, Inc., Inovio Pharmaceuticals, Inc., Mesa Laboratories, Inc., Johnson and Johnson, LHC Group, Inc., Natus Medical Inc., and Varex Imaging Corporation. J.A. Fields reports no disclosures relevant to the manuscript. D.S. Knopman serves on a Data Safety Monitoring Board for the DIAN study, has served on a Data Safety Monitoring Board for a tau therapeutic for Biogen but received no personal compensation, is a site investigator in Biogen aducanumab trials, is an investigator in clinical trials sponsored by Lilly Pharmaceuticals and the University of Southern California, serves as a consultant for Samus Therapeutics, Roche, Magellan Health and Alzeca Biosciences but receives no personal compensation, and receives research support from the NIH. D.T. Jones reports no disclosures relevant to the manuscript. R. Savica reports no disclosures relevant to the manuscript. V.K. Ramanan receives research funding from the NIH and the Mangurian Foundation for Lewy Body disease research and has provided educational content for Medscape unrelated to this work. T. Ferman receives funding from the Mangurian Foundation for Lewy body research and NIH. NR Graff-Radford reports no disclosures relevant to the manuscript. V.J. Lowe serves as a consultant for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc., AVID Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). Clifford R. Jack Jr. is employed by Mayo Clinic. He receives grant funding from the National Institutes of Health (R37 AG011378, R01 AG041851), the Alexander family professorship and the GHR Foundation. Within the past 36 months, he served on a DSMB for Roche pro bono; no payments to the individual or institution were involved. He has received funding from the Alzheimer’s Association for travel to scientific meetings. R.C. Petersen serves as a consultant for Roche, Inc., Merck, Inc., Biogen, Inc., Eisai, Inc., Genentech, Inc., and Nestle, Inc., served on a DSMB for Genentech, receives royalties from Oxford University Press and UpToDate, and receives NIH funding. B.F. Boeve has served as an investigator for clinical trials sponsored by Alector, Cognition Therapeutics, EIP Pharma, and Transposon. He serves on the Scientific Advisory Board of the Tau Consortium—funded by the Rainwater Charitable Foundation. He receives research support from NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the Ted Turner and Family Foundation. E.K. Louis has no disclosures related to this work. He has served as a Co-Investigator on K. Kantarci research grant (DLB U01) and as a NAPS co-investigator. J.T. O’Brien. has no conflicts related to this study; unrelated to this work he has received honoraria for work as DSMB chair or member for TauRx, Axon, Eisai, has acted as a consultant for Roche, and has received research support from Alliance Medical and Merck. K. Kantarci consults for Biogen, receives research support from Avid Radiopharmaceuticals and Eli Lilly, and receives funding from NIH and Alzheimer’s Drug Discovery Foundation. GS Day reports no competing interests directly relevant to this work. His research is supported by NIH (K23AG064029, U01AG057195, U01NS120901, U19AG032438). He serves as a consultant for Parabon Nanolabs Inc and as a Topic Editor (Dementia) for DynaMed (EBSCO). He is the co-Project PI for a clinical trial in anti-NMDAR encephalitis, which receives support from NINDS (U01NS120901) and Amgen Pharmaceuticals; and a consultant for Arialys Therapeutics. He has developed educational materials for Continuing Education Inc and Ionis Pharmaceutical. He owns stock in ANI pharmaceuticals. Dr. Day’s institution has received support from Eli Lilly for development and participation in an educational event promoting early diagnosis of symptomatic Alzheimer disease, and in-kind contributions of radiotracer precursors for tau-PET neuroimaging in studies of memory and aging (via Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly).